Nebivolol/rosuvastatin - Elyson Pharmaceutical

Drug Profile

Nebivolol/rosuvastatin - Elyson Pharmaceutical

Alternative Names: EL-1401

Latest Information Update: 07 Mar 2017

Price : $50

At a glance

  • Originator Elyson Pharm
  • Class Antihyperlipidaemics; Antihypertensives; Benzopyrans; Ethanolamines; Fluorobenzenes; Heart failure therapies; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hyperlipidaemia; Hypertension

Most Recent Events

  • 07 Mar 2017 Chemical structure information added
  • 31 Dec 2016 Elyson Pharmaceutical completes a phase I bioequivalence trial in South Korea (PO) before December 2016 (Elyson Pharmaceutical pipeline, February 2017)
  • 16 Nov 2016 Phase-III clinical trials in Hyperlipidaemia in South Korea (PO) (KCT0002148)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top